Contraindications
- Iron overload (hemochromatosis, hemosiderosis)
- Iron-utilization disorders (lead anemia, sideroachrestic anemia, thalassemia)
- Anemia not due to iron deficiency
- Hypersensitivity
Dosing: Adult
- Iron deficiency and iron-deficiency anemia (adults, adolescents over 12, pregnancy): 100 to 300 mg iron daily (1 to 3 chewable tablets), with or after meals
Dosing: Altered kidney function
Iron(III) hydroxide polymaltose complex is an oral iron whose absorbed iron is handled by normal iron metabolism, not the kidneys; unabsorbed iron leaves in feces. The Swedish label has very limited data in kidney impairment and gives no dose adjustment. It has no US FDA label.
Kidney function measure: Not renally cleared; the SmPC gives no kidney grading. Bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Iron deficiency (adults and adolescents over 12): 100 to 300 mg iron daily (1 to 3 chewable tablets), once or in divided doses, with or after meals; guide by hemoglobin and iron stores (SmPC).
- CrCl 30–59 mL/min
- No special dose recommendation needed (SmPC); oral iron is a first-line option in CKD not on dialysis.
- CrCl 15–29 mL/min
- No special dose recommendation needed (SmPC); oral iron is a first-line option in CKD not on dialysis.
- CrCl <15 mL/min (not on dialysis)
- No special dose recommendation needed (SmPC); oral iron is a first-line option in CKD not on dialysis.
- Hemodialysis (intermittent)
- No dialysis data in the SmPC. KDIGO 2026 prefers intravenous iron over oral iron in hemodialysis; oral iron is a second-line option.
- Peritoneal dialysis
- No PD data in the SmPC; oral iron may be used; intravenous iron if inadequate.
- CRRT
- No dialysis data in the SmPC.
- Dialyzable? Not applicable.
- Monitoring Hemoglobin, ferritin and transferrin saturation to guide dose and duration (SmPC 4.2). Do not combine with parenteral iron.
Children (kidney dosing)
- eGFR ≥60
- Tablets not for children 12 and under; no pediatric kidney data.
- eGFR 30–59
- Tablets not for children 12 and under; no pediatric kidney data.
- eGFR 15–29
- Tablets not for children 12 and under; no pediatric kidney data.
- eGFR <15 (not on dialysis)
- Tablets not for children 12 and under; no pediatric kidney data.
- Hemodialysis (intermittent)
- Tablets not for children 12 and under; no pediatric kidney data.
- Peritoneal dialysis
- Tablets not for children 12 and under; no pediatric kidney data.
- CRRT
- Tablets not for children 12 and under; no pediatric kidney data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: MPA (Sweden) product information (December 28, 2022). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Chewable tablets: over 12 years; younger children should use the drops (SmPC).
- Usual dose
- Over 12 years: adult dose.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Syrup: 50 mg/5 mL
- Oral drops: 50 mg/mL
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list Iron hydroxide polymaltose complex as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Iron Polymaltose Complex (1 product). Products registered under these spellings are included in the table and marked.
All registered products3
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
50 mg/5 mL SyrupAmber Glass Bottle x 30 mL, 60 mL and 120 mL (Box of 1's) | Rx | Osoth Inter Laboratories Co., Ltd.Thailand | Pacific Healthcare Philippines, Inc. | DR-XY39184 | Mar 16, 2031 | ||
FeriumIron (III) Hydroxide Polymaltose Complex | 50 mg/5 mL SyrupAmber Plastic Bottle x 60 mL and 150 mL | Rx | Emcure Pharmaceuticals Ltd.India | Genpharm, Inc. | DRP-2320 | Mar 6, 2028 | |
FeriumIron (III) Hydroxide Polymaltose Complex | 50 mg/mL Oral DropsAmber Plastic Bottle x 15 mL (Box of 1's) | Rx | Emcure Pharmaceuticals Ltd.India | Genpharm, Inc. | DRP-1060 | Apr 28, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Parenteral iron | Avoid | Oral absorption falls. | Do not combine. |
| Tetracyclines, aluminum hydroxide | Minor | No significant reduction in iron absorption (studies). | No action. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Dark stools
- Diarrhea, nausea, constipation, abdominal pain
Serious
- Urticaria, erythema (rare)
Monitoring parameters
- Hemoglobin, ferritin and transferrin saturation to guide dose and duration (SmPC 4.2). Do not combine with parenteral iron. Kidney
- Hemoglobin and iron indices
Pharmacokinetics
Key PK parameters
| Bioavailability | Absorbed actively in duodenum and jejunum; relative absorption falls with dose and rises with deficiency; not reduced by food |
|---|---|
| Metabolism (CYP, transporters) | Iron incorporated into hemoglobin or stored as ferritin |
| Renal excretion kidney | Not renal; unabsorbed iron in feces |
| Dialyzability kidney | Not applicable |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Swedish Medical Products Agency. Maltofer 100 mg chewable tablets SmPC [MPA (Sweden) product information, December 28, 2022; no US FDA label]. https://docetp.mpa.se/LMF/Maltofer%20100%20mg%20Chewable%20tablet%20SmPC_09001bee830cd20e.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Vifor France. (2022). Maltofer 100 mg tuggtabletter (iron(III) hydroxide polymaltose complex) [Produktresumé (summary of product characteristics); revised December 28, 2022]. Swedish Medical Products Agency (Läkemedelsverket). https://docetp.mpa.se/LMF/Maltofer%20100%20mg%20Chewable%20tablet%20SmPC_09001bee830cd20e.pdf
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2026). KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney International, 109(1S), S1–S99. https://doi.org/10.1016/j.kint.2025.06.006
- Hedayati, S. S., Babitt, J. L., Berns, J. S., Bozkurt, B., Cheung, R. S., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., Kim, S., Moura-Neto, J. A., Rossignol, P., Sahay, M., Tanaka, T., Wang, A. Y., Wheeler, D. C., Robinson, K. A., . . . Nagler, E. V. (2026). Evaluation and management of anemia in chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 clinical practice guideline. Annals of Internal Medicine. Advance online publication. https://doi.org/10.7326/ANNALS-26-02326
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .